## AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

# LISTING OF CLAIMS:

- 1. (currently amended) A method for managing batches of immunocompetent cells collected from human or animal subjects for deferred use, comprising for each of said human or animal subjects the following steps:
- A) a status-characterization step of collecting information characteristic of the status of health and/or the psychological status of said human or animal subject, said status-characterizing information being obtained by processing measurements made on samples selected from a group consisting of blood, fluid, secretions, hair and combinations thereof from said human or animal subject, said status-characterizing information yielding a subject status characterization result indicating the status of health status and/or the psychological status of said subject, and said collecting step further including
- i) collecting immunocompetent cells on said human or animal subject,
- ii) conditioning and preserving said collected cells in batches of immunocompetent cells, said batches being stored into one or more storage centers,

- iii) constituting from said collected cells, a personal cell library of immunocompetent cells, said personal cell library containing a sum of immunity information stored in the membranes of the collected immunocompetent cells from one or more of said batches of immunocompetent cells,
- B) processing said status-characterizing information, from the status-characterization step, for determining the subject's identity data, said identity data including immunity-related data, historical and clinical data on previous diseases, treatments and therapeutic protocols experienced by said subject,
- C) storing the subject's identity data, processed from successive status-characterization steps, into a cell management database,
- D) performing an identification of the batches of cells by consulting said cell management database, and receiving from said cell management database said subject's identity data, upon receiving a request concerning said subject from a cell treatment entity,
- E) determining a protocol of deferred use for said immunocompetent cells from said identified batches, by processing said subject's <u>identify</u> <u>identity</u> data received from said cell management database, and
- F) extracting selected ones of said immunocompetent cells from said personal cell library, according to said

determined deferred-use protocol, in view of re-using said selected cells into said subject.

- 2. (previously presented) The method according to claim 1, wherein the status-characterizing information comprise bioelectronic information resulting from processing respective measures of pH, oxidation-reduction potential Rh2 and resistivity  $\rho$  of blood previously collected on said human or animal subject.
- 3. (withdrawn) The method according to claim 1, wherein status-characterizing information comprise information obtained by processing sensible crystallization images of blood previously collected on said human or animal subject.

### 4-5. (canceled)

- 6. (withdrawn) The method according to claim 1, further comprising implementing said method in a therapeutic protocol including re-injecting lymphocytes on a human or animal subject, wherein the previously collected and preserved immunocompetent cells are submitted to an ex-vivo process before being re-injected.
- 7. (withdrawn) The method according to claim 6, further comprising implementing said method in a therapeutic protocol

including re-injecting lymphocytes T with a specific cytotoxic activity after ex-vivo expansion.

### 8-10. (canceled)

- 11. (withdrawn) The method according to claim 6, further comprising implementing said method in a therapy protocol including an ex vivo processing between lymphocytes and a vaccine before re-injection.
- 12. (withdrawn) The method according to claim 6, further comprising implementing said method in a therapy protocol including an ex vivo processing and an allergic desensitization of the lymphocytes before re-injection.
- 13. (withdrawn) The method according to claim 6, further comprising implementing said method in a therapy protocol including a step for re-injecting lymphocytes by the lymphatic way.
- 14. (withdrawn) The method according to claim 6, further comprising implementing said method in a therapy protocol for transfusing blood from a donor to a receiver, said protocol including substituting lymphocytes from said donor by lymphocytes from said receiver.

- 15. (previously presented) The method according to claim 1, further comprising implementing said method in a gene therapy protocol.
- 16. (previously presented) The method according to claim 1, further comprising cryo-preserving a batch of immunocompetent cells.
- 17. (previously presented) The method according to claim 20, further comprising before any re-use of a batch of immunocompetent cells previously collected, a step for checking the annihilation of the antibodies within said batch.
- 18. (previously presented) The method according to claim 1, further comprising during conditioning a batch of immunocompetent cells previously collected, a step for immunomagnetically selecting purified lymphocytes or monocytes.

#### 19. (canceled)

20. (previously presented) The system according to claim 32, further comprising means for getting status-characterizing by processing a blood sample collected on said human or animal subject.

- 21. (previously presented) The system according to claim 20, further comprising means for getting bio-electronic information by processing respective measures of the pH, the oxidation-reduction potential and the resistivity of blood previously collected on said human or animal subject.
- 22. (previously presented) The system according to claim 32, further comprising means for getting information from a capillary study of said human or animal subject's hair system.

23-24. (canceled)

- 25. (previously presented) The method according to claim 1, further comprising:
- processing said characteristic information in an information system for determining parameters of said deferreduse protocol, and
- storing said processed information in a cell management data base.

26-28. (canceled)

30. (currently amended) A method for managing batches of immunocompetent cells, the method comprising:

collecting successive batches of immunocompetent cells;

gathering information characteristic of health status and/or the psychological status of said subject, said status-characterizing information being obtained by analyzing samples of blood and/or fluid and secretions and/or hair collected from the subject before or during the immunocompetent cells collection;

determining the subject's identity data using said status-characterizing information, said personal cell library containing a sum of immunity information stored in the membranes of the collected immunocompetent cells;

storing the subject's identity data in a cell management database;

performing an identification of the collected cells by consulting said cell management database, and receiving from said cell management database said subject's identity data; anddetermining a protocol of deferred use for said immunocompetent cells from said identified batches, by processing said subject's identity data received from said cell management database.

31. (previously presented) A method for managing batches of preserved immunocompetent cells from a subject stored at one or more storage centers, the method comprising:

obtaining a request for the preserved cells of a subject;

identifying batches of the preserved cells for the subject using a cell management database containing subject's identity data including immunity-related data, historical and clinical data on previous diseases, treatments and therapeutic protocols experienced by said subject, said identification based receiving from said cell management database said subject's identity data;

determining parameters of a deferred-use protocol for said batches of immunocompetent cells; and

providing said identified batches and said deferred-use protocol parameters.

- 32. (previously presented) A system for managing braches of immunocompetent cells collected from human or animal subjects for their deferred use, said system comprising for each of said human or animal subjects:
- means for conditioning and preserving batches of immunocompetent cells successively collected, into one or more storage centers,
- means for constituting from said collected batches a personal library of immunocompetent cells, said personal library cumulating a sum of immunity information stored in the membranes of collected immunocompetent cells,
- means for collecting, during successive collections of batches, information that are characteristic of said human or

animal subject's status of health and/or psychological status, before or during immunocompetent cells collection, said status characterizing information is obtained by processing measurements made on samples of blood and/or fluid and secretions and/or hair collected on said human or animal subject,

- means for processing said status-characterizing information in view of determining said subject's identity data,
- means for storing said subject's identity data successively determined into a cell management database,
- $\,$  means for performing an identification of the batches of cells, and
- means for consulting said cell management database to perform the identification of the batches of cells by consulting said cell management database, and receiving from said cell management database said subject's identity data, said identity data including immunity-related data, historical and clinical data on previous diseases, treatments and therapeutic protocols experienced by said subject,
- means for managing said batch of immunocompetent cells by processing said successively collected subject's identity data to determine parameters of a deferred-use protocol for said identified batches of immunocompetent cells.
- 33. (previously presented) A system for managing batches of immunocompetent cells collected from human or animal

subjects for their deferred use, said system comprising for each of said human or animal subjects:

- a storage device for conditioning and preserving batches of immunocompetent cells successively collected, into one or more storage centers,
- a personal library processor for constituting from said collected batches a personal library of immunocompetent cells, said personal library cumulating a sum of immunity information stored in the membranes of collected immunocompetent cells,
- a collection device for collecting, during successive collections of batches, information that are characteristic of said human or animal subject's status of health and/or psychological status, before or during immunocompetent cells collection, said status characterizing information being obtained by processing measurements made on samples of blood and/or fluid and secretions and/or hair collected on said human or animal subject,
- a status-characterizing information device processing said status-characterizing information to determine said subject's identity data, said identity data including immunity-related data, historical and clinical data on previous diseases, treatments and therapeutic protocols experienced by said subject,

- a cell management database processor for storing said subject's identity data successively determined into a cell management database,
- an identification device for performing identification of the personal batches of cells and a consulting device for consulting said cell management database, and
- a processor for processing said successively collected subject's identity data to determine parameters of a deferred-use protocol for said identified batches of immunocompetent cells.
- 34. (previously presented) The device according to claim 33, further comprising a bio-electronic device for collecting bio-electronic information.
- 35. (currently amended) A method for managing batches of immunocompetent cells collected from a human subject for deferred use, comprising the steps of:
- A) a status-characterization step of collecting information characteristic of the health status and the psychological status of said human subject, the status-characterizing information comprising bioelectronic information resulting from processing respective measures of pH, oxidation-reduction potential Rh2, and resistivity  $\rho$  of blood collected from said subject,

said status-characterizing information yielding a subject status characterization result indicating the health status and the psychological status of said subject,

- if said subject status-characterization result indicates a correct evaluation, said status-characterization step further including
  - i) collecting immunocompetent cells on said subject,
- ii) conditioning and preserving said collected cells in batches of immunocompetent cells, and
- iii) constituting from said collected cells, a personal cell library of immunocompetent cells, said personal cell library containing a sum of immunity information stored in the membranes of the collected immunocompetent cells from one or more of said batches of immunocompetent cells;
- B) processing said status-characterizing information for determining the subject's identity data, said identity data including lymphocytes, immunity-related data, historical and clinical data on previous diseases, treatments and therapeutic protocols experienced by said subject;
- C) storing the subject's identity data, processed from the successive status-characterization steps, into a cell management database;
- D) responsive to a request concerning said subject from a cell treatment entity, performing an identification of the batches of cells by consulting said cell management database, and

receiving from said cell management database said subject's identity data;

- E) determining a protocol of deferred use for immunocompetent cells from said identified batches, by processing said subject's <u>identify</u> <u>identity</u> data received from said cell management database including checking for a harmlessness of the lymphocytes; and
- F) extracting selected immunocompetent cells from said personal cell library, according to said determined deferred-use protocol, and providing said extracted selected cells for reusing into said subject.